Related Experiment Video

Updated: Jul 17, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Inhibition of MITF transcriptional activity independent of targeting p300/CBP coactivators

Jiri Vachtenheim1, Blanka Sestáková, Zdena Tuhácková

  • 1Laboratory of Molecular Biology, University Hospital, Third Medical Faculty, Charles University Prague, Czech Republic. jivach@upn.anet.cz

Pigment Cell Research
|January 26, 2007
PubMed

Insights

Adenoviral E1A protein represses Microphthalmia-associated transcription factor (MITF) activity, independent of p300/CBP coactivators. This repression mechanism offers potential new avenues for melanoma therapy development.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Microphthalmia-associated transcription factor (MITF) is crucial for melanocyte development and survival.
  • MITF regulates key melanocyte-specific genes, but its own regulation is poorly understood.
  • MITF amplification in melanoma suggests its importance in malignant cell proliferation.

Purpose of the Study:

  • To investigate the mechanisms regulating MITF transcriptional activity.
  • To determine if adenoviral E1A protein can modulate MITF-driven transcription.
  • To explore potential therapeutic strategies targeting MITF in melanoma.

Main Methods:

  • Utilized U2-OS cells, a non-melanocytic cell line, to study MITF-driven tyrosinase transcription.
  • Employed adenoviral E1A protein and its specific domains (CR1, N-terminus) to assess their effects on MITF activity.
  • Generated MITF-CR1 chimeras and analyzed MITF mutants defective in p300/CBP binding.

Main Results:

  • Adenoviral E1A protein significantly repressed MITF-driven transcription in U2-OS cells.
  • The E1A CR1 domain was sufficient for repression, while the N-terminus was not.
  • CR1-mediated repression was largely independent of p300/CBP coactivators and PCAF-binding motif.
  • CR1 conferred transcriptional competence to a transcription-deficient MITF chimera.
  • MITF mutants unable to bind p300/CBP in vivo still activated transcription.

Conclusions:

  • MITF activity can be repressed by the E1A CR1 domain through a mechanism independent of canonical coactivators like p300/CBP.
  • Understanding E1A CR1-mediated repression of MITF may uncover novel therapeutic targets for melanoma.
  • MITF's role in melanoma proliferation highlights the significance of its regulatory mechanisms.

More Related Videos

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers10:28

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers

Published on: September 20, 2018

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C11:53

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C

Published on: June 1, 2018

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...